Table 1.

Reduction in CoNV area in the groups.

Groups	CoNV area (mm2) (first week)	CoNV area (mm2) (second week)	Change in CoNV area (mm2)	Percentage of reduction in CoNV area (%)	Pa
Control	17.31 ± 2.81	11.93 ± 2.64	5.29 ± 3.20	30.3%	0.028*
Subconjunctival bevacizumab	17.10 ± 2.98	4.85 ± 1.99	12.25 ± 4.28	69.9%	0.001***
Subconjunctival aflibercept	18.88 ± 3.78	6.66 ± 1.73	12.21 ± 2.91	64.5%	0.001***
Intrastromal bevacizumab	17.36 ± 4.52	2.83 ± 1.08	14.53 ± 4.93	82.5%	<0.001***
Intrastromal aflibercept	18.57 ± 4.16	2.63 ± 1.16	16.43 ± 4.19	88.1%	<0.001***
Pb	0.851	<0.001***	0.007**

Bold values indicate statistical significance.

^aWilcoxon signed-rank test was used to compare the CoNV areas at first week (before the treatment) with those at second week (1 week after the treatment).

^bKruskal–Wallis test was used to compare the CoNV areas at first and second week, and the change in CoNV area among the groups.